Leveraging T cell co-stimulation for enhanced therapeutic efficacy of trispecific antibodies targeting prostate cancer
Collectively, incorporating co-stimulatory receptor targeting domains represents a potentially effective strategy to unlock the full therapeutic potential of T-cell-engaging antibodies for the treatment of solid tumors.
Authors
- Jie Bi
- Liqiang Pan (ORCID: https://orcid.org/0000-0002-6557-8351)
- Jiaqi Zhao
- Yanping Sun (ORCID: https://orcid.org/0009-0004-3401-917X)
- Linling Zhou
- Xinyu Gu (ORCID: https://orcid.org/0009-0002-7539-8335)
Institutions
- Second Affiliated Hospital of Zhejiang University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1136/jitc-2024-010140
- Citations
- 8
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 8.36
Funders
- National Natural Science Foundation of China
- Zhejiang University
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases
- National Key Research and Development Program of China